What this is
- How it works
- How it works isn't classified yet
- Tested for
- Gout (2 trials), Hyperuricemia
- Main trialPhase 2
- “The aim of this study is to confirm the safety and pharmacological characteristics of SAP-001, evaluate its efficacy in lowering sUA and tophus burden, and identify the appropriate dose regimen for future studies in adult subjects with gout, with or without tophi, and hyperuricemia refractory to SoC XOI therapy.”In the company’s words, NCT05690204 on ClinicalTrials.gov
- Other names
- Xanthine Oxidase Inhibitor · Colchicine
Other drugs for Gout
- DapansutrileOlatec Therapeutics, Inc. · Phase 2/3
- EtoricoxibLaboratorios Silanes S.A. de C.V. · Phase 3
- DotinuradCrystalys Therapeutics · Phase 3
- AR882Arthrosi Therapeutics · Phase 2
- SSGJ-6133SBio · Phase 2
- PRX-115Protalix · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials38
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Jan 2025 | Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001. | |
| Phase 1/2Active, not recruiting | 17 Jan 2025 | PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function | |
| Phase 2Completed | 1 Aug 2020 | Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients | |
| Phase 1Completed | 2 Jun 2019 | Placebo Controlled, Dose Escalation Study to Evaluate Safety, Pharmacokinetics & Efficacy of SAP-001 in Gout Patients | |
| Phase 1Completed | 20 Dec 2023 | SAD,MAD and Food Effect Study of SAP-001 Tablets in Chinese Subjects | |
| Phase 3Authorised | not given | The Colchicine and atrial fibrillation trial | |
| Phase 2Authorised | not given | Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes (REC1TE): a randomized, double-blind, placebo-controlled, investigator-initiated trial | |
| Phase 3Ended | not given | Randomized double-blind trial to study the benefit of Colchicine in Patients with Acutely Decompensated Heart Failure | |
| Phase 3Authorised | not given | COLchicine in BElgium in patients with coronary artery disease after Percutaneous Coronary Intervention | |
| Phase 3Authorised | not given | EFFICACY OF COLCHICINE IN SECONDARY PREVENTION OF VASCULAR EVENTS AND RENAL PROGRESSION IN PATIENTS WITH MODERATE CHRONIC RENAL DISEASE (COLCHIREN STUDY). | |
| Phase 3Authorised | not given | The Colchicine heart failure preserved trial | |
| Phase 3Authorised | not given | COLchicine and Thiamine in Heart Failure due to Ischemic Heart Disease (COLT-HF) | |
| Phase 2Ended | not given | CONCISE COlchicine iN Circulating Inflammatory markers after StrokE | |
| Phase 2Authorised | not given | Colchicine for ischemia with no obstructive coronary artery disease and microvascular dysfunction | |
| Phase 3Authorised | not given | Use of oral colchicine to determine restenosis in the superficial femoral artery - the COLSTENT study | |
| Phase 3Authorised | not given | The Effect of ColcHicine on the incidence of knee or hip replacements: a randomized, double-blind, multicentre study in symptomatic knee or hip Osteoarthritis – the ECHO trial | |
| Phase 2Ended | not given | The COlchicine HypERtENsion Trial | |
| Phase 3Not authorised | not given | RECLAIM: an Adaptive Platform Trial for the Evaluation of Treatments for Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) | |
| Phase 3Authorised | not given | RECLAIM: an Adaptive Platform Trial for the Evaluation of Treatments for Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) | |
| Phase 3Authorised | not given | BIOmarker driven intensification of cardiovascular RISK factor management in patients with high risk for recurrent cardiovascular EVENTs | |
| Phase 3Authorised | not given | Low dose ColchicinE in pAtients with peripheral artery DiseasE to address residual vascular Risk: A randomized trial- LEADER PAD | |
| Phase 3Authorised | not given | Does Colchicine Reduce Progression of Aortic Valve Stenosis? Colchicine and Inflammation in Aortic Stenosis (CHIANTI): A placebo-controlled, double-blind, multicenter randomized trial. | |
| Phase 3Authorised | not given | RIISC Evaluation of low dose colchicine in prevention of ischemic stroke in patients with stroke due to atherosclerosis. Reducing inflammation in ischemic stroke with colchicine (riisc), | |
| Phase 3Authorised | not given | ARGO Colchicine versus Placebo in Acute Myocarditis Patients to Reduce Late Gadolinium Enhancement Mass on Cardiac Magnetic Resonance and the risk of Clinical Outcomes: The ARGO trial | |
| Phase 3Authorised | not given | Colchicine after Electrocardioversion for Atrial Fibrillation - The COLECTRO-AF Trial | |
| Phase 3Authorised | not given | COLchicine and non-enteric coated aspirin in the Cardiovascular Outcomes Trial of patients with Type 2 Diabetes (COLCOT-T2D) | |
| Phase 3Authorised | not given | Single-blinded randomized investigator-initiated controlled trial to assess the efficacy of colchicine to treat patients with cardiomyopathy with myocarditis (chronic inflammatory cardiomyopathy) – Trial and Registry to study the role of genotype environment interaction in Chronic myocarditis and inflammatory cardiomyopathies with ventricular pro-arrhythmic and heart failure phenotypes (PNRR-MAD-2022-12376225) | |
| Phase 3Authorised | not given | COLchicine to mitigate accelerated Atherosclerosis induced by immune checkpoint inhibitors in patients with cancer: the COLA trial | |
| Phase 2Authorised | not given | Randomized, controlled, double-blind trial to investigate the effect of colchicin on the endothelial function in patients with CHIP mutations and chronic heart failure with reduced left ventricular function (CHIP-HF) | |
| Phase 2Authorised | not given | A randomised, double-blind, multicenter, placebo-controlled clinical trial of colchicine to reduce coronary artery inflammation in people with HIV. COLCOHIV | |
| Phase 3/4Authorised | not given | Colchicine to reduce microvascular complications in people with type 1 diabetes and high glycemic variability | |
| Phase 2Authorised | not given | Colchicine to Quench the Inflammatory Response after Deep Vein Thrombosis: The CONQUER-DVT Randomized Controlled Trial | |
| Phase 2Authorised | not given | The effect of colchicine, on insulin sensitivity in individuals with type 1 diabetes and systemic low-grade inflammation (INS1GHT) | |
| Phase 3Authorised | not given | Multicenter and randomised study on atrial fibrillation prevention after cardiac surgery with a 3-way comparison between standard of care, posterior pericardiotomy and a treatment bundle (colchicine, amiodarone and posterior pericardiotomy) (PREV-AF) | |
| Phase 3Authorised | not given | Colchicine for the Reduction of Dependency and Vascular Events after an Acute Intracerebral Hemorrhage (CoVasc-ICH2) | |
| Phase 2Not authorised | not given | Repurposed Drug Evaluation for Biological Aging, Pain, and Inflammation Reduction in Osteoarthritis | |
| Phase 4Authorised | not given | Colchicine Assessment of Low-grade Inflammation and Biomarker Response in Atherosclerosis with Targeted Evaluation | |
| Phase 2Authorised | not given | A RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, CLINICAL TRIAL OF COLCHICINE IN AMYOTROPHIC LATERAL SCLEROSIS (CO-ALS II) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026